Skip to main content

Day: December 19, 2022

Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc

NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced the following amendments to the terms of the previously announcement arrangement agreement with Midatech Pharma plc (NASDAQ:MTP; AIM:MTPH) (“Midatech”):Midatech is no longer required to seek delisting from AIM following completion of the arrangement; andthe US$750,000 bridge loan to be provided by Midatech to Bioasis will now be advanced...

Continue reading

Soil Moisture Meter Market Size [2022-2029] | Industry Share, Trends, and Growth Forecast Analysis

Soil Moisture Meter Market Major Manufacturers Covered in The Market Report Include: The Toro Company, Sentek Technologies, Delta-T Devices Ltd, Trellis, Inc., Spectrum Technologies, Inc., Vegetronix, Inc., R. TURONI S.R.L, METER Group, Inc., Lincoln Irrigation Company, FLIR Systems, Inc. Pune, India, Dec. 19, 2022 (GLOBE NEWSWIRE) — Increasing demand from the sports sector to maintain the grounds is a key factor expected to enable the growth of the market, says Fortune Business Insights, in a report, titled “Soil Moisture Meter Market Size, Share & Industry Analysis, By Type (Volumetric, Tensiometers, Solid-State Sensors), By Application (Agriculture, Residential, Sports Turf, Forestry, Construction & Mining, Research Studies, Others (Landscaping, Ground Care)) and Regional Forecast, 2019-2026” The increasing concern...

Continue reading

Freshii to be Acquired by Foodtastic Inc.

All-cash consideration of $2.30 per share delivers significant and immediate value to all Freshii shareholders Consideration represents a 148% premium to 20-day volume-weighted average price per share for the period ending on December 16, 2022 and a 142% premium to the closing price on December 16, 2022 Expected to help accelerate Freshii brand growth and profitability for franchisee partners Process overseen by a special committee of independent directors and unanimously approved by Freshii’s board Matthew Corrin, Freshii’s founder, has entered into a voting support agreement to support the transactionTORONTO, Dec. 19, 2022 (GLOBE NEWSWIRE) — Freshii Inc. (TSX: FRII) today announced that it has entered into an arrangement agreement pursuant to which Foodtastic Inc. will acquire all of the issued and outstanding shares of Freshii...

Continue reading

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS). The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-year. There are currently no FDA-approved medications for CIAS, a major cause of disability in 80% of patients with schizophrenia1. Topline results are expected in the first half of 2024.NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) — Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its Phase 2b proof-of-concept clinical trial for RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS),...

Continue reading

Asensus Announces Senhance System Placement at GPR Klinikum Rüsselsheim of Germany

10th hospital in Germany to initiate a Senhance SystemThe Senhance Surgical System The Senhance Surgical System advances clinical intelligence by providing surgeons with augmented intelligence and digital tools to perform consistently superior surgery.RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that GPR Gesundheits- und Pflegezentrum Klinikum of Rüsselsheim (“GPR”), Germany has entered into an agreement to lease and utilize a Senhance® Surgical System. “With GPR’s broad laparoscopic use, the Senhance Surgical System is a perfect fit for high-volume surgical specialities like gynecology, urology...

Continue reading

Oil Storage Terminal Market size worth USD 42.13 billion by 2029 | Industry expected to rise at a CAGR of 4.4%

The global oil storage terminal market size was USD 30.15 billion in 2021. The market is projected to grow USD 42.13 billion by 2029, at a CAGR of 4.4% Pune, India, Dec. 19, 2022 (GLOBE NEWSWIRE) — The global oil storage terminal market is expected to rise during the forecast period owing to the rising demand for energy and increasing requirement of various crude oil products in different applications. Fortune Business Insights™ shares this information in a report titled, “Oil Storage Terminal Market, 2022-2029”. As per the report, the oil storage terminal market size was USD 30.15 billion in 2021. The market size is expected to rise from USD 31.14 billion in 2022 to USD 42.13 billion by 2029 at a CAGR of 4.4% during the forecast period. Oil storage terminals are core elements of the oil & gas production...

Continue reading

Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

— Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations — — Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma — WOODCLIFF LAKE, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has approved an additional indication for PEMFEXY® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrations....

Continue reading

With 14.4% CAGR, Short Bowel Syndrome Market Size to Surpass Around USD 2,213.5 Billion by 2029

According to Fortune Business Insights, Short Bowel Syndrome Market to Reach USD 2,213.5 million by 2029; Rising Awareness of Rare Diseases and the Growing Need and Demand for Advanced Products Stimulates Market Growth Pune, India, Dec. 19, 2022 (GLOBE NEWSWIRE) — The short bowel syndrome market size was valued at USD 737.9 million in 2021. It is projected to reach from USD 865.3 million in 2022 to USD 2,213.5 million by 2029 at a CAGR of 14.4% during the forecast period. The market is anticipated to propel due to the extended use of approved drugs to treat both pediatric and adult populations. Fortune Business Insights™ stated this in a report titled, “Global Short Bowel Syndrome Market, 2022-2029.” Key Industry Development:June 2022: U.S.-based firm, 9 Meters Biopharma, Inc. declared the optimistic results...

Continue reading

Stantec selected to design the California High-Speed Rail extension from Merced to Madera

US$41 million contract will include design services for 33.9-mile extension EDMONTON, Alberta and NEW YORK and LOS ANGELES, Dec. 19, 2022 (GLOBE NEWSWIRE) — NYSE, TSX:STN Stantec, a global leader in sustainable design and engineering, has been selected to design the California High-Speed Rail Authority’s extension from Merced to Madera, a key section between Los Angeles and San Francisco. The extension covers 33.9 miles and will include 40 structures. The Merced to Madera design contract is valued at US$41 million, which is expected to be delivered over about two years. Stantec will finalize the project configuration footprint, advance design work to refine costs and travel-time enhancements, and map right-of-way needs and utility relocations. The Merced to Madera section is the key junction that will connect the 500-mile-long...

Continue reading

Bovine Gelatin Market to Reach USD 1.88 Billion by 2029 | Fortune Business Insights™

Companies covered in Bovine Gelatin Market are NITTA GELATIN, INC. (Japan), Lapi Gelatin S.p.A. (Italy), Jellice Pioneer Europe B.V. (Netherlands), Darling Ingredients Inc. (U.S.), Gelita AG (Germany), Merck KGaA (Germany), Lonza Group (Switzerland), Bernard Jansen Products Inc. (U.S.) , Luoyang Leston Import and Export Trade Co., Ltd. (China), Nutra Food Ingredients, LLC (U.S.) and more players profiled. Pune, India, Dec. 19, 2022 (GLOBE NEWSWIRE) — The global bovine gelatin market size was USD 1.13 billion in 2021. The market is projected to grow from USD 1.21 billion in 2022 to USD 1.88 billion by 2029, exhibiting a CAGR of 6.46% during the 2022-2029 period. This information is provided by Fortune Business Insights, in its report titled, “Bovine Gelatin Market, 2022-2029.” List of Key Players Mentioned in the Report:NITTA...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.